We compare the efficacy, adverse events, and recovery duration of etomidate and propofol for use in procedural sedation in the emergency department (ED). A randomized nonblinded prospective trial of adult patients undergoing procedural sedation for painful procedures in the ED was made. Patients received either propofol or etomidate. Doses, vital signs, nasal end-tidal CO~2~(etco~2~), pulse oximetry, and bispectral electroencephalogram analysis scores were recorded. Subclinical respiratory depression was defined as a change in etco~2~greater than 10 mmHg, an oxygen saturation of less than 92% at any time, or an absent etco~2~waveform at any time. Clinical events related to respiratory depression, including an increase in supplemental oxygen, the use of a bag-valve-mask apparatus, airway repositioning, or stimulation to induce breathing, were noted. Etomidate and propofol appear equally safe for ED procedural sedation. Etomidate had a lower rate of procedural success and induced myoclonus in 20% of patients (see Table [1](#T1){ref-type="table"}).

  Agent                                Etomidate (*n*= 53)      Propofol (*n*= 55)                             
  ------------------------------------ ------------------------ ---------------------- ----------------------- ----------------------
  Subclinical respiratory depression   Yes (*n*= 18)            No (*n*= 35)           Yes (*n*= 23)           No (*n*= 32)
  Increased supplemental oxygen        1/9 (2.1, 0.9--11.2)     2/34 (2.9, 0.8--7.2)   2/23 (4.4, 1.2--14.4)   1/32 (1.6, 0.2--5.5)
  Bag-valve mask (%)                   2/18 (6.9, 1.9--13.9)    0/34 (0, 0--2.3)       2/23 (4.4, 1.4--11.9)   0/32 (0, 0--2.7)
  Airway repositioning                 3/18 (9.7, 2.9--16.0)    3/34 (5.1, 1.4--8.7)   3/23 (6.5, 1.5--11.6)   3/31 (4.7, 1.1--8.0)
  Stimulation to induce breathing      4/18 (11.1, 5.1--19.6)   2/34 (2.9, 0.8--7.1)   3/23 (7.6, 3.2--14.5)   3/31 (4.7, 1.8--9.6)
